episodic migraine
Neurology · 2020–2020
1decision
1medicine
1carried consumer input
48individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| galcanezumab Treatment of episodic migraine in adult patients who have experienced an inadequate response, intolerance, or a contraindication to at least three prophylactic… | Nov 2020 | Not recommended | 48 individuals Migraine Australia |
Who spoke
Migraine Australia
What the PBS pays
$48M in government benefit over 2024–25, across 85,214 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| galcanezumab | $48.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.